Moreover, scopolamine contributes directly to the AD pathology by increasing Aβ levels and deposition (possibly due also to augmented β-site amyloid precursor protein cleaving enzyme 1 (BACE1) expression and activity [44] and the amount of phosphorylated tau protein [44,45,46,47]. This evidence concerns the gene MAPT and Alzheimer disease.